Logo
Login
$ACRV
$1.72 -$0.01 (0.58%) Close

Company Executives

$ACRV Management Team

Dr. Peter Blume-Jensen

Chairman of the Board

President

Chief Executive Officer

Age 63
Compensation $2.000M USD
Sex Male

Dr. Eric Devroe

Chief Operating Officer

Age 47
Compensation $1.147M USD
Sex Male

Dr. Kristina Masson

Executive Vice President - Business Operations

Director

Age 45
Compensation $1.197M USD
Sex Female

Dr. Erick Gamelin

Chief Development Officer

Age 68
Compensation $538.1K USD
Sex Male

Dr. Adam Levy

Chief Financial Officer

Principal Financial Officer

Age 60
Compensation -
Sex Male

Mrs. Mary-Alice Miller

Chief Legal Officer

Age 51
Compensation $697.0K USD
Sex Female

Dr. Raza Mirza

Chief Medical Officer

Age 64
Compensation -
Sex Male

Board of Directors

From the proxy statement filed Apr 30, 2026
Directors
8
serving now
Independent
6 of 8
stated in the proxy
Average tenure
4.8 years
from year joined
CEO also chairs the board
Yes
Peter Blume-Jensen
Director Age On board Independent Committees Other public boards 2025 pay Source
Michael Tomsicek
60 2022
4 years
 Independent
Audit Committee · Chair
Milestone Pharmaceuticals USA, Inc. $72,870
Charles Baum
68 2023
3 years
 Independent
Compensation Committee · Chair
PMV Pharmaceuticals, Inc. Not stated
Kristina Masson
Executive officer
 46 2018
8 years
 Not independent None stated None stated Not stated
Sharon Shacham
55 2020
6 years
 Independent
Compensation Committee
Nasus Pharma, Ltd. Not stated
Ivana Magovčević-Liebisch
58 2024
2 years
 Independent
Audit Committee
Draig Therapeutics, Ltd. Not stated
Peter Blume-Jensen
Board chair, CEO
 64 2018
8 years
 Not independent None stated None stated Paid as CEO
Derek DiRocco
45 2021
5 years
 Independent
Audit Committee
Mineralys Therapeutics, Inc. Not stated
Santhosh Palani
43 2024
2 years
 Independent
Nominating and Governance Committee · Chair
Pyxis Oncology Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

4 disclosed in the proxy filed Apr 30, 2026
RA Capital Healthcare Fund, L.P.
a beneficial owner of greater than 5% of our capital stock
$30,005,000
April 8, 2024

Purchased 3,530,000 shares of common stock in the April 2024 Private Placement at $8.50 per share.

Open in proxy
Perceptive Life Sciences Master Fund, Ltd.
a beneficial owner of greater than 5% of our capital stock
$20,000,500
April 8, 2024

Purchased 2,353,000 shares of common stock in the April 2024 Private Placement at $8.50 per share.

Open in proxy
Sands Capital Life Sciences Pulse Fund II, L.P.
a beneficial owner of greater than 5% of our capital stock
$3,995,000
April 8, 2024

Purchased 470,000 shares of common stock in the April 2024 Private Placement at $8.50 per share.

Open in proxy
Citadel CEMF Investments Ltd.
an entity affiliated with Citadel Advisors LLC, a beneficial owner of greater than 5% of our capital stock
$3,995,000
April 8, 2024

Purchased 470,000 shares of common stock in the April 2024 Private Placement at $8.50 per share.

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans